ECX.F - Epigenomics AG

Frankfurt - Frankfurt Delayed Price. Currency in EUR
-0.010 (-0.262%)
At close: 8:04AM CET
Stock chart is not supported by your current browser
Previous Close3.815
Bid3.805 x 100000
Ask3.830 x 100000
Day's Range3.805 - 3.805
52 Week Range3.515 - 7.421
Avg. Volume4,385
Market Cap91.375M
PE Ratio (TTM)N/A
EPS (TTM)-0.390
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.35
  • PR Newswire7 months ago

    Epigenomics Commences Post Approval Study on Epi proColon®

    BERLIN, and GERMANTOWN, Md. , Aug. 30, 2017 /PRNewswire/ -- Epigenomics AG (Frankfurt Prime Standard: ECX) (OTCQX: EPGNY), today announced the initiation of a Post Approval Study (PAS), Performance of ...

  • Zacks Small Cap Research8 months ago

    VNRX: Large U.S. Study Comes Cheap, Could Support Asymptomatic FDA Filing

    VNRX is required to contribute just $3M (paid in equal quarterly installments over 3 years), with most of the funding borne by the study's main sponsor, the U.S. National Cancer Institute's (NCI) Early Detection Network (EDRN), which is the leading cancer research organization in the U.S.  The Great Lakes New England Clinical Validation Center and the University of Michigan are also major participants and, along with EDRN, focused on the pursuit of technologies for the early detection of cancer. • will include ~13.5k asymptomatic screening samples from subjects 50 years of age who have not previously undergone colonoscopy or CRC screening.

  • We're sorry this is all we were able to find about this topic.